Stabilux Biosciences, Inc

New biomedical discovery is driving the need to find improved methods to identify novel and rare biomarkers. Early cancer detection, drug discovery, mRNA vaccines, immunology all rely on accurate detection of rare biomarkers and measurement of many biomarkers at the same time. After a decade of pioneering materials development at Michigan Technological University, StabiLux Bright Technology is now set to provide a platform that elevates biomedical research by detecting previously undetectable markers. This includes rapidly identifying markers like troponin released during cardiac arrest and spotting cancer markers in their earliest stages. StabiLux High Brightness Dyes will help discover, detect and monitor these biomarkers and is poised to unleash the next wave of biomedical Innovation.